121 related articles for article (PubMed ID: 9396396)
1. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study.
Maulard-Durdux C; Toubert ME; Hennequin C; Housset M
J Clin Oncol; 1997 Dec; 15(12):3446-50. PubMed ID: 9396396
[TBL] [Abstract][Full Text] [Related]
2. Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study.
Maulard C; Toubert ME; Chretien Y; Delanian S; Dufour B; Housset M
Cancer; 1994 Jan; 73(2):394-8. PubMed ID: 8293406
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer.
Menéndez López V; Galán JA; Fernández-Suárez A; López-Celada S; Alcover J; Filella X
Urology; 2003 Aug; 62(2):243-8. PubMed ID: 12893327
[TBL] [Abstract][Full Text] [Related]
4. Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer.
Bennink R; Van Poppel H; Billen J; Decoster M; Baert L; Mortelmans L; Blanckaert N
Anticancer Res; 1999; 19(4A):2609-13. PubMed ID: 10470203
[TBL] [Abstract][Full Text] [Related]
5. [Tissue polypeptide antigen (TPA) in urological malignancies. I. S-TPA in bladder cancer patients].
Akiyama T; Tsujihashi H; Boku E; Nagai N; Matsuura T; Iguchi M; Yachiku S; Kurita T
Hinyokika Kiyo; 1983 Dec; 29(12):1635-40. PubMed ID: 6677110
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology.
Bantis A; Zissimopoulos A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Athanassiadou P; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2010; 13(3):213-7. PubMed ID: 21193872
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
8. [Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma].
Tizzani A; Casetta G; Cavallini A; Piana P; Piantino P
Minerva Urol Nefrol; 1990; 42(2):69-71. PubMed ID: 2392743
[TBL] [Abstract][Full Text] [Related]
9. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
10. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of tissue polypeptide antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer.
Hefler L; Tempfer C; Frischmuth K; Maenner G; Concin N; Sliutz G; Reinthaller A; Leodolter S; Kainz C
Tumour Biol; 2000; 21(2):98-104. PubMed ID: 10686539
[TBL] [Abstract][Full Text] [Related]
12. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
13. Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.
Stefanović V; Mitić-Zlatković M; Ignjatović I; Vlajković M; Sćepović Z
Int Urol Nephrol; 1999; 31(4):443-9. PubMed ID: 10668938
[TBL] [Abstract][Full Text] [Related]
14. [A basic and clinical evaluation of a new immunoradiometric assay kit for human serum tissue polypeptide antigen (TPA)].
Shimojo K; Watanabe N; Sakai S; Kobayashi M; Ohtake H; Hatori N; Fukasawa K; Tomiyoshi K; Inoue T; Endo K
Kaku Igaku; 1996 Jun; 33(6):655-61. PubMed ID: 8741511
[TBL] [Abstract][Full Text] [Related]
15. Tissue polypeptide antigen (TPA) in urinary bladder cancer cytology: a follow-up study.
Senatore S; Zizzi L; Blasi C; Alfieri G; Saccani Jotti G; Gabrielli M; Luccarelli S
Oncology; 1990; 47(1):37-42. PubMed ID: 2300382
[TBL] [Abstract][Full Text] [Related]
16. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L
Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.
van der Gaast A; Kirkels WJ; Blijenberg BG; Splinter TA
J Cancer Res Clin Oncol; 1992; 118(8):626-8. PubMed ID: 1517284
[TBL] [Abstract][Full Text] [Related]
18. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports.
Senatore S; Attolini A; Luccarelli S; Candita F; Trabucco M
Oncology; 1987; 44(2):118-23. PubMed ID: 2437508
[TBL] [Abstract][Full Text] [Related]
20. Urine-TPA (tissue polypeptide antigen), flow cytometry and cytology as markers for tumor invasiveness in urinary bladder carcinoma.
Carbin BE; Ekman P; Eneroth P; Nilsson B
Urol Res; 1989; 17(5):269-72. PubMed ID: 2815427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
